当前位置: 首页 > 期刊 > 《中国医学创新》 > 2025年第11期
编号:2317395
富马酸伏诺拉生联合莫沙必利治疗反流性食管炎的效果
http://www.100md.com 2025年6月4日 中国医学创新 2025年第11期
     Effect of Vonoprazan Fumarate Combined with Mosapride in Treatment of Reflux Esophagitis/YU Jinbo, LI Zhonghua, WEI Lihua. //Medical Innovation of China, 2025, 22(11): 099-103

    [Abstract]Objective: To observe the efect of Vonoprazan Fumarate combined with Mosapride in the treatment ofreflux esophagitis.Method:According totherandom numbertable method, 80 patients with reflux esophagitis admitted to Shangrao People's Hospitalfrom January 2023 to April 2024 were divided into two groups, with 40 cases each.Thecontrol groupwas treated with Vonoprazan Fumarate,and the observation group was treated withMosaprideonthebasisofontrolgroup.Theclinicalefficacyadversereactions,laboratoryindexes anddisease indexes beforeand after treatment were comparedbetweenthetwo groups.Result:After treatment,gastrointestinal hormones,inflammatoryfactors anddiseaseindicators inthe observation group werebeter than those inthe control group, with statistical significance ( P lt;0.05). After treatment, the total effective rate of the observation group was higher than that of the control group, the difference was statistically significant ( P lt;0.05). There was no significant difference in the incidence of adverse reactions between the two groups ( P gt;0.05). Conclusion: Vonoprazan Fumarate combined with Mosapride has a good efect in thetreatment of reflux esophagitis ......

您现在查看是摘要页,全文长 13121 字符